Optimising CDK4/6 Inhibitor Therapy in HR+/HER2− Breast Cancer

Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Earn CME points and track your learning activity with hundreds of hours of continuing medical education.

Optimising CDK4/6 Inhibitor Therapy in HR+/HER2− Breast Cancer

This module provides an evidence-based overview of CDK4/6 inhibitors in HR+/HER2− breast cancer, including disease biology, clinical evidence, genomic testing, treatment pathways, and case-based learning to support best practice.

Module

English

1 CME Points

Save

Complete Complete

Target audience

This module is intended for medical oncologists, specialist breast cancer nurses, oncology trainees, and other healthcare professionals involved in the multidisciplinary management of patients with hormone receptor-positive (HR+)/HER2− breast cancer.

Learning objectives

By the end of this module, learners will be able to:

Describe the biological rationale for CDK4/6 inhibition and its role in the management of HR+/HER2− breast cancer.
Evaluate the current clinical evidence supporting the use of CDK4/6 inhibitors across early and metastatic HR+/HER2− breast cancer.
Interpret the role of multigene assays and genomic biomarkers in recurrence risk assessment, treatment selection, and therapeutic sequencing.
Apply evidence-based treatment strategies to optimise patient selection, treatment sequencing, and multidisciplinary management across the disease continuum.
Recognise key treatment-related adverse events and implement appropriate monitoring, patient education, and supportive care strategies to optimise adherence and outcomes.
Integrate clinical evidence and genomic information into therapeutic decision-making through practical, case-based scenarios.

Optimising CDK4/6 Inhibitor Therapy in HR+/HER2− Breast Cancer

Target audience

Learning objectives

More from ecancer